CA3024744A1 - Methods for subtyping of lung squamous cell carcinoma - Google Patents

Methods for subtyping of lung squamous cell carcinoma Download PDF

Info

Publication number
CA3024744A1
CA3024744A1 CA3024744A CA3024744A CA3024744A1 CA 3024744 A1 CA3024744 A1 CA 3024744A1 CA 3024744 A CA3024744 A CA 3024744A CA 3024744 A CA3024744 A CA 3024744A CA 3024744 A1 CA3024744 A1 CA 3024744A1
Authority
CA
Canada
Prior art keywords
sample
biomarker
nucleic acids
expression
classifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024744A
Other languages
English (en)
French (fr)
Inventor
Hawazin FARUKI
Myla LAI-GOLDMAN
Greg MAYHEW
Jonathan Serody
Charles Perou
David Neil Hayes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Genecentric Therapeutics Inc
Original Assignee
University of North Carolina at Chapel Hill
Genecentric Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Genecentric Therapeutics Inc filed Critical University of North Carolina at Chapel Hill
Publication of CA3024744A1 publication Critical patent/CA3024744A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Informatics (AREA)
  • Databases & Information Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
CA3024744A 2016-05-17 2017-05-17 Methods for subtyping of lung squamous cell carcinoma Pending CA3024744A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662337645P 2016-05-17 2016-05-17
US62/337,645 2016-05-17
US201662379402P 2016-08-25 2016-08-25
US62/379,402 2016-08-25
US201662396587P 2016-09-19 2016-09-19
US62/396,587 2016-09-19
US201662420836P 2016-11-11 2016-11-11
US62/420,836 2016-11-11
US201662425717P 2016-11-23 2016-11-23
US62/425,717 2016-11-23
PCT/US2017/033107 WO2017201164A1 (en) 2016-05-17 2017-05-17 Methods for subtyping of lung squamous cell carcinoma

Publications (1)

Publication Number Publication Date
CA3024744A1 true CA3024744A1 (en) 2017-11-23

Family

ID=60325556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024744A Pending CA3024744A1 (en) 2016-05-17 2017-05-17 Methods for subtyping of lung squamous cell carcinoma

Country Status (6)

Country Link
US (2) US11041214B2 (enExample)
EP (1) EP3458611B1 (enExample)
JP (1) JP7241352B2 (enExample)
CN (1) CN109863251B (enExample)
CA (1) CA3024744A1 (enExample)
WO (1) WO2017201164A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116287253A (zh) * 2023-02-22 2023-06-23 武汉科技大学 一种肺癌分子标志物及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950623A1 (en) 2014-05-30 2015-12-03 Myla LAI-GOLDMAN Methods for typing of lung cancer
CA3002196C (en) 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
AU2017260630B2 (en) 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
US11041214B2 (en) 2016-05-17 2021-06-22 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
WO2017201165A1 (en) 2016-05-17 2017-11-23 Genecentric Diagnostics, Inc. Methods for subtyping of lung adenocarcinoma
WO2019160914A1 (en) 2018-02-13 2019-08-22 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
EP3864165A4 (en) 2018-10-09 2022-08-03 Genecentric Therapeutics, Inc. DETECTION OF ORIGIN CANCER CELLS
DE102018125324A1 (de) * 2018-10-12 2020-04-16 Universität Rostock Verfahren zur Vorhersage einer Antwort auf die Therapie von Krankheiten
WO2021041726A1 (en) * 2019-08-27 2021-03-04 Exact Sciences Development Company, Llc Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
CN111369501B (zh) * 2020-02-24 2022-04-01 武汉大学 一种基于视觉特征识别口腔鳞状细胞癌的深度学习方法
CN111653312B (zh) * 2020-05-28 2021-04-16 上海宝藤生物医药科技股份有限公司 一种利用基因组数据探究疾病亚型亲缘性的方法
CN111755073B (zh) * 2020-05-31 2022-11-15 复旦大学 基于转录组的pd-1疗法治疗效果预测系统
CN112433054A (zh) * 2020-11-20 2021-03-02 四川大学华西医院 C9蛋白检测试剂在制备肺癌筛查试剂盒中的用途
GB202103200D0 (en) * 2021-03-08 2021-04-21 Terasom S R O Lung Cancer diagnosis
WO2022226391A1 (en) * 2021-04-23 2022-10-27 The Trustees Of Columbia University In The City Of New York Methods for detecting squamous cancer
CN115308418B (zh) * 2022-07-07 2024-11-08 翁良 一种生物标志物及其在肺鳞癌诊断中的应用
CN115982644B (zh) * 2023-01-19 2024-04-30 中国医学科学院肿瘤医院 一种食管鳞状细胞癌分类模型构建与数据处理方法
CN116129998B (zh) * 2023-01-19 2024-06-11 中国医学科学院肿瘤医院 一种食管鳞状细胞癌数据的处理方法及其系统
EP4741516A1 (en) * 2024-11-12 2026-05-13 Tempus AI, Inc. Methods and systems for classifying cancer and detecting improved cancer therapies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1337667A2 (en) 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP2007006792A (ja) 2005-06-30 2007-01-18 Hitachi Software Eng Co Ltd 肺腺癌の胸膜浸潤を判別するための遺伝子セット
WO2008151110A2 (en) 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US20110224313A1 (en) 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival
CN101509035A (zh) 2008-09-05 2009-08-19 中国人民解放军总医院 肺癌分型的基因序列及其应用
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US20150293098A1 (en) * 2012-06-18 2015-10-15 The University Of North Carolina At Chapel Hill Methods for head and neck cancer prognosis
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
EP3037547A1 (en) 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
CA2950623A1 (en) 2014-05-30 2015-12-03 Myla LAI-GOLDMAN Methods for typing of lung cancer
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3283654A4 (en) 2015-04-14 2018-12-12 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
WO2017201165A1 (en) 2016-05-17 2017-11-23 Genecentric Diagnostics, Inc. Methods for subtyping of lung adenocarcinoma
US11041214B2 (en) 2016-05-17 2021-06-22 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
US11739386B2 (en) 2017-07-21 2023-08-29 Genecentric Therapeutics, Inc. Methods for determining response to PARP inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116287253A (zh) * 2023-02-22 2023-06-23 武汉科技大学 一种肺癌分子标志物及其应用

Also Published As

Publication number Publication date
JP7241352B2 (ja) 2023-03-17
EP3458611A4 (en) 2020-02-26
EP3458611B1 (en) 2023-11-08
CN109863251A (zh) 2019-06-07
US20190338366A1 (en) 2019-11-07
US11041214B2 (en) 2021-06-22
US12139765B2 (en) 2024-11-12
WO2017201164A1 (en) 2017-11-23
EP3458611A1 (en) 2019-03-27
JP2019516406A (ja) 2019-06-20
US20210340631A1 (en) 2021-11-04
CN109863251B (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
US12139763B2 (en) Methods for subtyping of lung adenocarcinoma
US12139765B2 (en) Methods for subtyping of lung squamous cell carcinoma
US12006554B2 (en) Methods for subtyping of head and neck squamous cell carcinoma
US20230395263A1 (en) Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
US11851715B2 (en) Detecting cancer cell of origin
US12195805B2 (en) Methods for subtyping of bladder cancer
EP3149209B1 (en) Methods for typing of lung cancer
JP2019516406A5 (enExample)
US11739386B2 (en) Methods for determining response to PARP inhibitors
WO2021262696A2 (en) Methods for selecting and treating cancer with fgfr3 inhibitors
US20240182984A1 (en) Methods for assessing proliferation and anti-folate therapeutic response
US20250191689A1 (en) Methods for subtyping and treatment of head and neck squamous cell carcinoma
HK40006869A (en) Methods for subtyping of lung squamous cell carcinoma
HK40006869B (en) Methods for subtyping of lung squamous cell carcinoma
HK40006868B (en) Methods for subtyping of lung adenocarcinoma
HK40006868A (en) Methods for subtyping of lung adenocarcinoma
WO2025259592A1 (en) Therapeutic predictive response signatures and uses thereof in cancer patients

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220513